Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of MYK-224 in heart failure with preserved ejection fraction
CTR20253079Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BMS-986435 in heart failure with preserved ejection fraction (HFpEF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of TEAEs, SAEs, and adverse events leading to treatment discontinuation. Started Nov 2025; status: active.
02
Drugs
BMS-986435
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on CTR20253079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253079.